STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1282 by analyst upside · 2026-08-13
INSM
Insmed Incorporated
Healthcare · Market Cap $29B · P/E 0x
ANALYST PRICE TARGET
+51.2%
implied upside to consensus target
Current Price $132.28
Consensus Target $200.05
Bull Target $243.0
Bear Target $169.0
Analysts Covering 22
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
17
Hold
0
Sell
0
52-Week Low $90.39
52-Week High $212.75
YTD Return -25.3%
FUNDAMENTALS
Market Cap $29B
P/E Ratio (TTM) N/A
Forward P/E 155.3x
EPS (TTM) $-4.12
PEG Ratio 1.09
Dividend Yield N/A
Revenue (TTM) $1.1B
Profit Margin -76.9%
52-WEEK RANGE
52-Week Low $90.39
52-Week High $212.75
Current Price $132.28
Bear Target $169.0
Bull Target $243.0
● Now $132.28 ● Target $200.05
TRADING DATA
Avg Volume 3.8M
YTD Return -25.3%
Analyst Count 22
Consensus Buy
Upside to Target +51.2%
Last Updated 2026-08-13

ANALYST SUMMARY

Insmed Incorporated (INSM) is currently trading at $132.28 with a Wall Street consensus price target of $200.05, implying potential upside of 51.2% over the next 12 months. 22 analysts currently cover INSM, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $243.0, while the most cautious has a target of $169.0.

INSM operates in the Healthcare sector with a market capitalisation of $29B. The stock is down 25.3% year-to-date and is currently trading near the lower end of its 52-week range of $90.39 – $212.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for INSM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-06-08 43% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-06-05 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-05-14 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-08 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-05-08 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-05-08 62% win rate (8 calls)
Roth Capital reit
Buy → Buy 2026-04-17 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-04-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
70
out of 100
Coverage depth
24/30
Consensus clarity
19/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →